These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 33495204)

  • 41. Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation.
    Baker D; Wilsmore B; Narasimhan S
    Intern Med J; 2016 Jul; 46(7):792-7. PubMed ID: 27040617
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Differences in the management of patients with atrial fibrillation according to whether primary care or the specialist initiates treatment with direct oral anticoagulants. The SILVER-AP and BRONCE-AP studies].
    de la Figuera M; Prieto MA; Marín N; Egocheaga I; Cinza S;
    Semergen; 2018; 44(5):323-334. PubMed ID: 29174522
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gender and Socioeconomic Inequality in the Prescription of Direct Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation in Primary Care in Catalonia (Fantas-TIC Study).
    Dalmau Llorca MR; Aguilar Martín C; Carrasco-Querol N; Hernández Rojas Z; Forcadell Drago E; Rodríguez Cumplido D; Castro Blanco E; Pepió Vilaubí JM; Gonçalves AQ; Fernández-Sáez J
    Int J Environ Res Public Health; 2021 Oct; 18(20):. PubMed ID: 34682739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation.
    Brais C; Larochelle J; Turgeon MH; Blais L; Farand P; Perreault S; Letemplier G; Beauchesne MF
    J Pharm Pharm Sci; 2017; 20():8-14. PubMed ID: 28459661
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?].
    Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L
    Semergen; 2018; 44(5):297-303. PubMed ID: 28867369
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study.
    Gedikli Ö; Altay S; Ünlü S; Çakmak HA; Aşkın L; Yanık A; Beşli F; Sinan ÜY; Canpolat U; Şahin M; Pehlivanoğlu S
    Anatol J Cardiol; 2021 Mar; 25(3):196-204. PubMed ID: 33690135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.
    Henk HJ; Cao F; Tuell K; Price K; Singh P; Mardekian J; Odell K; Patel C; Tan W; Sands GH; Singhal S; Trocio J; Vo L
    Curr Med Res Opin; 2018 Mar; 34(3):539-546. PubMed ID: 29235900
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras.
    Brown JD; Shewale AR; Dherange P; Talbert JC
    Drugs Aging; 2016 Jun; 33(6):427-36. PubMed ID: 27154397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of Direct Oral Anticoagulant Prescribing in Patients With Moderate to Severe Renal Impairment.
    Ting C; Rhoten M; Dempsey J; Nichols H; Fanikos J; Ruff CT
    Clin Appl Thromb Hemost; 2021; 27():1076029620987900. PubMed ID: 33517715
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of stroke and bleed events in non-valvular atrial fibrillation patients with direct oral anticoagulant prescriptions in NHS England between 2013 and 2016.
    Sheth H; McNally D; Santibanez-Koref M; Burn J
    PLoS One; 2019; 14(6):e0218878. PubMed ID: 31233554
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determinants for under- and overdosing of direct oral anticoagulants and physicians' implementation of clinical pharmacists' recommendations.
    Moudallel S; Cornu P; Dupont A; Steurbaut S
    Br J Clin Pharmacol; 2022 Feb; 88(2):753-763. PubMed ID: 34331720
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Right drug, wrong dosage: insights from the PAVE-AF antithrombotic study in older patients with atrial fibrillation.
    Tzeis S; Savvari P; Skiadas I; Patsilinakos S; Stamatelopoulos K; Kourouklis S; Kyrikos S; Tsatiris K; Menegas D; Hahalis G; Giannakoulas G;
    J Thromb Thrombolysis; 2021 Jan; 51(1):81-88. PubMed ID: 32519166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 54. Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.
    Essien UR; Holmes DN; Jackson LR; Fonarow GC; Mahaffey KW; Reiffel JA; Steinberg BA; Allen LA; Chan PS; Freeman JV; Blanco RG; Pieper KS; Piccini JP; Peterson ED; Singer DE
    JAMA Cardiol; 2018 Dec; 3(12):1174-1182. PubMed ID: 30484833
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.
    See LC; Lee HF; Chao TF; Li PR; Liu JR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; Lip GYH
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):975-986. PubMed ID: 33211254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing.
    Moudallel S; Steurbaut S; Cornu P; Dupont A
    Front Pharmacol; 2018; 9():1220. PubMed ID: 30425641
    [No Abstract]   [Full Text] [Related]  

  • 57. Effectiveness and Safety of Direct Oral Anticoagulants in the Secondary Stroke Prevention of Elderly Patients: Ljubljana Registry of Secondary Stroke Prevention.
    Frol S; Sernec LP; Hudnik LK; Šabovič M; Oblak JP
    Clin Drug Investig; 2020 Nov; 40(11):1053-1061. PubMed ID: 32886321
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
    Russo V; Cattaneo D; Giannetti L; Bottino R; Laezza N; Atripaldi U; Clementi E
    Clin Ther; 2021 Sep; 43(9):e255-e263. PubMed ID: 34366151
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system.
    Grant SJ; Kothari S; Gimotty PA; Gooneratne NS; Cuker A
    J Thromb Thrombolysis; 2018 Jul; 46(1):1-6. PubMed ID: 29611105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.